SEGMENT REPORTING (Tables)

3 Months Ended

Mar. 31, 2025

Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle

The following table reconciles reported revenues to net (loss) income under the significant expense principle for the three months ended March 31, 2025 and 2024:


	MARCH 31, 2025		MARCH 31, 2024
Revenues:
Product revenue, net	$	39.4	$	—
Royalties	0.2		0.3
Total revenues	$	39.6	$	0.3
Operating expenses:
Cost of goods sold	1.2		—
Research and development
Research and clinical expenses	13.7		16.4
Chemistry, manufacturing, and control expenses	1.5		11.2
Selling, general and administrative
Commercial expenses	20.0		11.3
Other segment expenses*	19.9		17.5
Total operating expenses	$	56.3	$	56.4
Loss from operations	(16.7)		(56.1)
Total interest and other income (expense)	(3.1)		0.7
Net loss	$	(19.8)	$	(55.4)